►Managing the Migraine Patient: A Case for Communication
Program Overview:
Migraine is the most common of all neurological disorders and by far the most common headache condition seen in primary care. Fortunately for today’s patients and clinicians, there are approaches to acute and preventive therapy that can make this disabling headache disorder an eminently manageable one. Advances available today include both medication options and treatment strategies that can target the process of migraine, not merely dull its symptoms. Today’s management options include proven acute and preventive treatments as well as optimized strategies for implementing effective care. In addition, strategies around patient communication can empower patients to obtain their optimal treatment outcomes. As better understanding of the pathophysiological process of migraine has unfolded, new treatment options that target the mechanism of migraine are currently in clinical trials and potentially may provide new options for patients in the future.
This activity will provide an up-to-the-minute overview of acute and preventive migraine management as well as the latest evidence for effective communication strategies for migraine patients. A dynamic case-based approach to many of the most commonly encountered clinical questions in migraine will be addressed by this faculty of experts with neurology and primary care backgrounds. Participants will gain a solid understanding of the best evidence-based approaches to migraine as well as the clinical pearls that can bring the management of migraine back to the patients in the clinic.
Learning Objectives:
After completing this activity, the participant will be able to:
Be familiar with approaches to the management of the acute migraine attack
Recognize options for the preventive treatment of the migraine patient
Understand approaches for improving communication with migraine patients and strategies for implementing in office practice
Be aware of new therapeutic targets for acute and preventive migraine treatment
Accreditation/Designation Statement:
Primary Care Network, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Primary Care Network designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Target Audience: This activity is targeted to all physicians and other healthcare professionals who treat patients with migraine headache.
Release Date: February 10, 2009 Expiration Date: February 10, 2010
Medium: Online CME
Acknowledgment of Commercial Support: This activity was developed from the live American Osteopathic Association’s 113th Annual Convention & Scientific Seminar in Las Vegas, NV on October 29, 2008 which was supported through an educational grant from Merck & Co, Inc.
Method of Participation: To receive CME credit for this activity, you need to review the program (slides and audio). Upon finishing the online CME, complete the post-test, evaluation, and fill out all required personal information. To receive your CME certificate you will need to pass the post-test with 70% accuracy or better.
Post-test and Evaluation:
After completing this activity, click on the Post-test button at the end of the program. If you receive less than 70% on the post-test, you will be returned to the beginning of the activity to review the presentation again. Upon successful completion of the post-test, you will be asked to fill out a program evaluation form and prompted to print your CME certificate.
Statement of Disclosure and Independence
It is the policy of Primary Care Network, Inc. to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, Primary Care Network has Conflict of Interest and Disclosure Policies that are designed to ensure that Primary Care Network sponsored educational activities are fair balanced, independent, evidence‐based and based on scientific rigor.
Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a Primary Care Network sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
The opinions, ideas, recommendations, and perspectives expressed in the accompanying presentations at this Primary Care Education program are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, Primary Care Education, Advisory Boards and Consultants, or the activity’s commercial supporters.
Planning Committee and Disclosures:
Dr. Roger K. Cady is a consultant for Aradigm Corporation, GlaxoSmithKline, Jazz Pharmaceuticals, Merck & Co., Inc., and Ortho-McNeil Neurologics. He serves on the advisory board for Allergan, Atrix Laboratories, Inc., Capnia Inc., Endo Pharmaceuticals, GlaxoSmithKline, Med-Pointe, Merck & Co., Inc., and Ortho-McNeil Neurologics. Dr. Cady has received grant support from Advanced Bionics, Alizyme, Allergan, Alexza, BioAlliance, Capnia Inc., Forest Pharmaceuticals, GlaxoSmithKline, Jazz Pharmaceuticals, King Pharmaceuticals, MAP Pharmaceuticals, Merck & Co., Inc., Minster Pharmaceuticals, Neuralieve, Novartis, Ortho-McNeil Neurologics, Pfizer Inc., Schwarz Biosciences, Torrey Pines Therapeutics, Wyeth, and Zogenix.
Dr. David W. Dodick is on the advisory board for Allergan, Coherex, Endo Pharmaceuticals, HS Lundbeck, Johnson & Johnson, MAP Pharmaceuticals, Merck & Co., Inc., Neuralieve, and Pfizer Inc. He is a consultant for Allergan and Merck & Co., Inc. Dr. Dodick also receives grant support from Advanced Neurostimulation Systems and Medtronic.
Dr. Loretta Mueller serves on the speaker’s bureau and receives research grants from GlaxoSmithKline and Merck & Co., Inc. She is on the advisory board for Merck & Co., Inc. and receives research grants from Endo Pharmaceuticals.
Dr. Curtis P. Schreiber has received grant support from Advanced Neuromodulation, Alexza AMDC, Allergan, Alizyme, BioAlliance, Boston Scientific, Capnia, GlaxoSmithKline, Jazz Pharmaceuticals, King, MAP, Merck & Co., Minster Pharmaceuticals, Neuralieve, Novartis, Nupathe, Pfizer Inc., Schwarz Biosciences, Torrey Pines Therapeutics, and Zogenix.
Dr. James A. Voirin is on the speaker’s bureau for Elan, GlaxoSmithKline, Merck & Co., Inc., Ortho-McNeil, and Pfizer Inc. He is on the advisory board for Ortho-McNeil and has received grant support from Merck & Co., Inc.
Faculty:
Roger K. Cady, MD
Director, Headache Care Center
Springfield, MO
James A. Voirin, DO
Director, Physician Associates Headache Center
Orlando, FL.
Loretta Mueller, DO
Associate Professor of Family Medicine, University of Medicine and Dentistry
New Jersey-School of Osteopathic Medicine
Director, University Headache Center
Stratford, NJ
David W. Dodick, MD
Professor of Neurology, Mayo Clinic College of Medicine
Consultant in Neurology, Mayo Clinic
Phoenix, AZ
Unlabeled Use Declaration
During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.
Review Committee Disclosure In accordance with our policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.
Curtis P. Schreiber, MD has received research grant support from Abbott, Advanced Bionics, Alexza AMDC, Allergan, Alizyme, BioAlliance, GlaxoSmith Kline, Jazz Pharmaceuticals, King, MAP, Merck & Co., Minster Pharmaceuticals, Neuralieve, Novartis, Ortho-McNEil, Pfizer, Schering-Plough, Schwarz, Biosciences, Torrey Pines Therapeutics, and Zogenix.
